Clinical Trials Logo

Filter by:
NCT ID: NCT05993481 Recruiting - Clinical trials for Hypotension During Surgery

The Noninvasive Blood Pressure Measurement Effect on the Hypotension

Start date: April 17, 2024
Phase: N/A
Study type: Interventional

Around 300 million surgical operations are performed globally, and of these, 40 to 50 million are performed in the USA. The perioperative period is characterized by hemodynamic instability and, most importantly, hypotension. Intraoperative hypotension is frequent, and the incidence ranges between 5% and 99% during non-cardiac surgery, depending on the definition. The aim of the study is determined as the relationship between two different time intervals of measurements and time spent hypotensive under harm thresholds in non-cardiac surgery in adults having non-cardiac surgery. Secondarily, it will be determined if more frequent non-invasive blood pressure measurement use decreases postoperative acute kidney injury. Exploratory, it will be evaluated if more frequent non-invasive blood pressure use causes pain or nerve injury in the arms or not.

NCT ID: NCT06030622 Recruiting - Clinical trials for Pancreatic Cancer Metastatic

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

C3
Start date: April 17, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goals of this trial are: 1) To evaluate the safety and tolerability of C3 administration with Gemcitabine; and 2) To assess the disease response following C3 administration with Gemcitabine. The main question it aims to answer are: 1) Is C3 in combination with Gemcitabine safe, tolerable, and effective for reducing improving advanced stage pancreatic cancer? and 2) Can C3 in combination with Gemcitabine prolong the lives of patients with advanced stage pancreatic cancer. Participants will receive a combination of metformin (850 mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day), also known as C3, and Gemcitabine (as per standard of care) for 2 years. If patients decline Gemcitabine, they will be offered the C3 medications only.

NCT ID: NCT06082973 Recruiting - Type 1 Diabetes Clinical Trials

Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge

TAILOR/3
Start date: April 17, 2024
Phase: N/A
Study type: Interventional

The present clinical trial aims to examine alternative strategies for preventing/mitigating hypoglycemic events among adults with type 1 diabetes utilizing a highly personalized control system. This system offers two configurable options: a single-hormone configuration with automatic rescue carbohydrate recommendations (sHC) and a dual-hormone configuration with subcutaneously administered glucagon boluses (dHmG). The main question addressed in this study focuses on determining whether the dHmG outperforms the sHC in terms of minimizing the time spent below the target range and number of hypoglycemic events. Each participant will undergo two 12-hour controlled inpatient studies, including each an unannounced 30-min aerobic exercise session and a meal challenge. The order of these studies, comparing the dHmG to the sHC, will be randomized.

NCT ID: NCT06105515 Recruiting - Gastric Cancer Clinical Trials

Laparoscopic and Endoscopic Collaborative Surgery as Rescue-treatment for Advanced Gastric Cancer

LE-RACUS
Start date: April 17, 2024
Phase: N/A
Study type: Interventional

The standard treatment for advanced gastric cancer without metastases is gastrectomy, where the whole stomach or a large proportion is removed surgically together with regional lymph nodes. Some patients cannot tolerate this invasive procedure because of old age or comorbidities. A tumor left in place can cause local symptoms such as bleeding or outlet obstruction. In this study, the investigators want to test the safety and feasibility of Laparoscopic and Endoscopic Collaborative Surgery (LECS) as a less invasive treatment option to locally remove gastric tumors without requiring extensive surgery in these frail patients. LECS is a minimally invasive surgical technique where the tumor margin is first marked from the inside with a gastroscope, followed by surgical removal of the lesion under endoscopic guidance.

NCT ID: NCT06113016 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors

PROFFi
Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.

NCT ID: NCT06114745 Recruiting - Clinical trials for Alzheimer's Disease (AD)

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Start date: April 17, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.

NCT ID: NCT06114888 Recruiting - Clinical trials for Community-acquired Pneumonia

Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics

PRESTO-1
Start date: April 17, 2024
Phase: N/A
Study type: Interventional

Children are commonly hospitalized because of community-acquired pneumonia. Despite the fact that many of these children have viral disease, a majority is treated with antibiotics. These antibiotics will not accelerate recovery in those with viral pneumonia and can cause harm. We are interested in exploring whether the MeMed BV - a composite biomarker assay - could be used to improve antibiotic prescribing in these children by identifying those who likely have viral disease. This proposal describes a feasibility randomized trial of this diagnostic intervention.

NCT ID: NCT06123468 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Start date: April 17, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma

NCT ID: NCT06125340 Recruiting - Clinical trials for Community-acquired Pneumonia

Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy

PRESTO-2
Start date: April 17, 2024
Phase: Phase 4
Study type: Interventional

Children are commonly hospitalized because of community-acquired pneumonia (CAP). There are multiple high-quality randomized trials of short-course antibiotic therapy (3-5 days of treatment) for adults hospitalized with CAP - but there is very little evidence in children. We intend to do a pilot RCT of short-course (3-5 days) vs standard-duration (8-10 days) antibiotic therapy for children hospitalized for CAP.

NCT ID: NCT06150469 Recruiting - Clinical trials for Hematological Malignancies

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

AROM-HEMATO
Start date: April 17, 2024
Phase: N/A
Study type: Interventional

This project will optimise the management of chemotherapy-induced nausea and vomiting, with improvements in nausea and vomiting scores, quality of life and appetite expected in participants benefiting from the intervention. In all cases, the use of complementary methods is recommended and improves the management of people with cancer because they offer a person-centred approach.